NVO stock news · Novo Nordisk
Get alerts for NVO
Follow Novo Nordisk (NVO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVOThe FDA says kids 10 and up with type 2 diabetes can use Awiqli® with a weekly shot.
Good for NVOThe FDA approved Awiqli for children 10 years and older with type 2 diabetes. Weekly dosing gives Novo Nordisk a useful new treatment option for this group.
Novo Resources Corp. shares new findings about soil tests at the Belltopper Project.
Good for NVONovo's Belltopper soil clues point to altered ground and possible gold targets. This is a modestly favorable sign, but it does not confirm a discovery.
OpenAI has purchased a biotech company to help scientists create medicines more quickly.
NeutralOpenAI bought a drug-research software startup and cited work with Novo Nordisk. The article gives no new Novo Nordisk project or result, so it does not change the company's outlook.
New ETF from REX Shares focuses on the growing peptide market, not just Eli Lilly and Novo Nordisk.
NeutralNovo Nordisk is named among the drugmakers leading the GLP-1 market as a new fund covers a wider peptide field. The article cites growing demand but reports no new Novo sales or business change, so Novo's outlook is unchanged.
The drug industry is suing the Trump administration, saying the new Medicare drug pricing rule is illegal and unfair.
NeutralNovo Nordisk has a White House pricing deal, and CMS plans to exempt such firms from a rule expected to reach few drugs. PhRMA’s suit seeks to block it, but the savings estimate fell to $440 million over 7 years from $11.9 billion, leaving Novo Nordisk’s outlook little changed.
The FDA is taking more time to decide on Novo Nordisk's hemophilia drug.
Bad for NVONovo Nordisk's FDA review of denecimig was extended after a factory inspection. The delay puts its planned launch at risk, despite no safety or trial-data findings.
Anthropic is spending $100 million to train 10,000 AI engineers by 2027 as it gets ready to go public.
NeutralNovo Nordisk engineers are included in Anthropic's new AI training program. The story reports no company result from their participation, so it does not change Novo Nordisk's outlook.
More than 88% of people in the Wegovy study reached healthy liver fat levels, says Novo.
Good for NVONovo Nordisk reported lower liver fat in a small group taking Wegovy. The finding supports its work on fatty liver disease, but the study was limited.
Novo Nordisk says its new obesity drug helps people eat less and lose weight.
Good for NVONovo Nordisk reported weight loss in CagriSema studies and among Wegovy pill users. The findings support its obesity-drug business, though CagriSema is still under review.
A scientist challenges Anthropic Claude's claim of a big discovery, saying he studied the enzymes for four years already.
NeutralNovo plans to use Anthropic’s models for software work and wider AI use. But the article reports no medicine result and questions a separate Claude discovery, so it does not show a clear change for Novo.
Why is Novo Nordisk's stock moving up and down on Friday?
NeutralNovo Nordisk set drug-growth goals and signed a deal to develop longer-lasting treatments, but its main drug faces patent loss and stronger competition. The plans do not yet settle that challenge.
Today, there are big trades happening in 10 health care stocks.
NeutralThe article lists a Novo Nordisk call trade tagged neutral. It reports no company news, so it does not change the company's outlook.
Big investors are making moves in 10 health care stocks today.
Bad for NVONovo Nordisk had a call option trade labeled bearish; 3,345 contracts were traded at the $40 strike expiring Oct 16, 2026.
Shares of Novo Nordisk, Telix Pharmaceuticals, and other major companies dropped before the market opened on Monday.
Bad for NVONovo Nordisk published Phase 3 topline results and shares fell; the market read the data as disappointing for Cagrisema.
Congressman sells big tech stocks and buys shares in everyday brands like McDonald's and Pepsi.
NeutralA congressman bought $1,000-$15,000 of Novo Nordisk; a single small buy is not a company-level development for Novo Nordisk.
The EMA Committee supports Novo Nordisk's treatment for Hemophilia A.
Good for NVOThe EMA committee recommended FREHEMGO and Novo struck a cardiometabolic research deal; I view this as a positive development for Novo Nordisk.
A Novo Nordisk analyst is now less optimistic; check out the four biggest downgrades for Friday.
Bad for NVOMorgan Stanley downgraded Novo Nordisk to Underweight and kept a $40 target; I read this as unfavorable for Novo Nordisk.
FDA Issues Alert on Misleading GLP-1 Weight Loss Medications.
NeutralSemaglutide-related harms are linked to illicit products rather than branded drugs, and FDA enforcement may protect legitimate sales, leaving mixed implications for Novo Nordisk.
Nine additional pharmaceutical partnerships announced by Trump increase total agreements to 26 — RFK Jr. shares insights on 'deeply emotional' discussions with the President.
Bad for NVONovo Nordisk is explicitly noted as expecting that higher prescription volumes will take time to offset revenue declines from lower U.S. drug prices.
According to an optimistic analyst, Hims & Hers Health requires investments to achieve sustainable incremental growth.
Good for NVOThe renewed partnership with Hims & Hers is expected to drive growth through strong demand for GLP-1 offerings.
Amazon Pharmacy introduces affordable weight-loss medications at $50 monthly for Medicare beneficiaries.
Good for NVOIncreased accessibility to Novo's weight-loss drugs through Amazon could boost sales and market penetration.
Dutch court rules in favor of Novo Nordisk, suspending sales of unapproved semaglutide nasal spray.
NeutralNovo Nordisk scored a significant legal victory as a Dutch court halted the sales of an unauthorized semaglutide nasal spray, reinforcing the company's intellectual property rights and protecting its established products. This ruling is expected to bolster investor confidence in Novo Nordisk's market position amidst ongoing competition in the GLP-1 space.